Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AMLX

AMLX - Amylyx Pharmaceuticals, Inc. Stock Price, Fair Value and News

18.54USD+3.23 (+21.10%)Market Closed
Watchlist

Market Summary

USD18.54+3.23
Market Closed
21.10%

AMLX Alerts

  • Point72 Asset Management, L.P. reported owning 4.1% of AMLX [2024-02-14]
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

AMLX Stock Price

View Fullscreen

AMLX RSI Chart

AMLX Valuation

Market Cap

1.3B

Price/Earnings (Trailing)

25.51

Price/Sales (Trailing)

3.3

EV/EBITDA

19.62

Price/Free Cashflow

117.69

AMLX Price/Sales (Trailing)

AMLX Profitability

EBT Margin

14.26%

Return on Equity

11.37%

Return on Assets

9.52%

Free Cashflow Yield

0.85%

AMLX Fundamentals

AMLX Revenue

Revenue (TTM)

380.8M

Rev. Growth (Yr)

82.05%

Rev. Growth (Qtr)

5.61%

AMLX Earnings

Earnings (TTM)

49.3M

Earnings Growth (Yr)

111.08%

Earnings Growth (Qtr)

-77.36%

Breaking Down AMLX Revenue

Last 7 days

-1.6%

Last 30 days

0.6%

Last 90 days

31.6%

Trailing 12 Months

-53.4%

How does AMLX drawdown profile look like?

AMLX Financial Health

Current Ratio

5.66

AMLX Investor Care

Shares Dilution (1Y)

1.91%

Diluted EPS (TTM)

0.7

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023111.9M201.5M291.1M380.8M
20225.8M11.3M16.7M22.2M
2021000285.0K

Tracking the Latest Insider Buys and Sells of Amylyx Pharmaceuticals, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jan 25, 2024
milne george m jr
gifted
-
-
-9,100
-
Jan 16, 2024
milne george m jr
gifted
-
-
-94,350
-
Jan 09, 2024
yeramian patrick d
sold
-45,914
16.3281
-2,812
chief medical officer
Jan 09, 2024
frates james m
sold
-44,347
16.3281
-2,716
chief financial officer
Jan 09, 2024
klee justin b.
sold
-95,372
16.3281
-5,841
co-chief executive officer
Jan 09, 2024
cohen joshua b
sold
-95,372
16.3281
-5,841
co-chief executive officer
Dec 27, 2023
olinger margaret
acquired
9,250
0.37
25,000
chief commercial officer
Dec 15, 2023
firestone karen
bought
59,880
14.97
4,000
-
Nov 27, 2023
bedrosian camille l
acquired
-
-
58,333
chief medical officer
Nov 16, 2023
cohen joshua b
acquired
99,999
1.57
63,694
co-chief executive officer

1–10 of 50

Which funds bought or sold AMLX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 21, 2024
Raleigh Capital Management Inc.
new
-
109,575
109,575
0.05%
Feb 20, 2024
Quarry LP
reduced
-85.00
-80,510
11,040
-%
Feb 20, 2024
EVENTIDE ASSET MANAGEMENT, LLC
unchanged
-
-4,009,440
16,439,800
0.27%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
132
2,993
-%
Feb 16, 2024
SageView Advisory Group, LLC
new
-
39,803
39,803
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
added
25.6
33,071
70,607
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
reduced
-39.94
-13,516
27,198
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
added
3,594
12,728,000
13,172,000
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
reduced
-12.02
-8,168
37,790
-%
Feb 16, 2024
Hobbs Group Advisors, LLC
new
-
323
323
-%

1–10 of 43

Are Funds Buying or Selling AMLX?

Are funds buying AMLX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AMLX
No. of Funds

Unveiling Amylyx Pharmaceuticals, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
viking global investors lp
4.4%
2,962,555
SC 13G/A
Feb 14, 2024
perceptive advisors llc
2.8%
1,869,125
SC 13G/A
Feb 14, 2024
point72 asset management, l.p.
4.1%
2,751,305
SC 13G/A
Feb 13, 2024
vanguard group inc
7.81%
5,275,566
SC 13G/A
Jan 29, 2024
blackrock inc.
5.9%
4,002,334
SC 13G
Dec 11, 2023
point72 asset management, l.p.
4.7%
3,176,105
SC 13G
Oct 04, 2023
morningside venture investments ltd
3.43%
2,313,227
SC 13D/A
Aug 17, 2023
morningside venture investments ltd
6.86%
4,618,846
SC 13D/A
Jun 09, 2023
goldman sachs group inc
5.4%
3,653,782
SC 13G
Apr 03, 2023
morningside venture investments ltd
12.92%
8,618,846
SC 13D/A

Recent SEC filings of Amylyx Pharmaceuticals, Inc.

View All Filings
Date Filed Form Type Document
Feb 22, 2024
10-K
Annual Report
Feb 22, 2024
8-K
Current Report
Feb 22, 2024
S-8
Employee Benefits Plan
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Jan 29, 2024
4
Insider Trading
Jan 29, 2024
SC 13G
Major Ownership Report
Jan 18, 2024
4
Insider Trading

Peers (Alternatives to Amylyx Pharmaceuticals, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Amylyx Pharmaceuticals, Inc. News

Latest updates
Marketscreener.com45 minutes ago

Amylyx Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q3
Revenue5.6%108,449,000102,693,00098,216,00071,428,00059,570,83347,713,66735,856,50023,999,33312,142,167285,000
Costs and Expenses26.8%106,515,00083,973,00078,015,00073,481,00066,478,00055,026,00054,253,00047,814,000-23,203,000
Operating Expenses-------54,253,00047,814,000--
  S&GA Expenses7.2%52,241,00048,718,00043,391,00044,006,00040,844,00029,940,00029,994,00026,350,00014,921,00010,350,000
  R&D Expenses49.5%44,914,00030,037,00029,044,00024,192,00022,813,00024,914,00024,259,00021,464,00013,394,00012,853,000
EBITDA Margin535.4%0.150.02-0.35-1.32-8.87-10.96-13.58-20.97-308-
Income Taxes17.0%1,776,5001,518,0001,900,000-200,000566,500-100,000174,000146,000--
Earnings Before Taxes-71.1%6,476,00022,411,00024,007,0001,403,000-42,125,000-53,881,000-53,893,000-47,702,000-28,344,000-23,142,000
EBT Margin628.8%0.140.02-0.35-1.33-8.89-10.98-13.60-20.99-308-
Net Income-77.4%4,731,00020,893,00022,074,0001,573,000-42,704,000-53,756,000-54,067,000-47,848,000-28,344,000-23,142,000
Net Income Margin1951.9%0.130.01-0.36-1.33-8.92-10.99-13.63-21.01-308-
Free Cashflow338.8%13,195,000-5,526,0008,331,000-5,322,000-50,317,000-43,537,000-47,567,000-40,976,000-28,430,000-21,018,000
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q4
Assets10.9%517467454408391181225274106
  Current Assets7.0%465434427389382172216265105
    Cash Equivalents25.8%17013524811563.0010867.0011050.00
  Inventory18.4%38.0032.0025.0013.0010.001.00---
  Net PPE-2.7%3.003.003.003.003.002.002.001.000.00
Liabilities74.4%84.0048.0067.0055.0051.0037.0032.0033.0017.00
  Current Liabilities79.8%82.0046.0064.0052.0047.0033.0027.0028.0017.00
Shareholder's Equity3.6%4334183863533411441932415.00
  Retained Earnings1.5%-304-309-330-352-354-311-257-203-155
  Additional Paid-In Capital1.4%7387287177056954564514455.00
Shares Outstanding0.3%68.0068.0067.0067.0067.0056.0055.0052.007.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Cashflow From Operations362.2%13,551-5,1698,609-5,072-49,697-43,078-46,462-40,634-28,244-20,865-13,047-12,643
  Share Based Compensation-6.3%9,53410,1769,9507,5016,0915,5245,7074,3921,091802657586
Cashflow From Investing119.4%20,925-108,088123,22255,994-228,18084,0414,462-99,3112,814-49,206--14.00
Cashflow From Financing-74.1%2308891,3841,040232,162--828200,455-1,065131,6511,99325,927

AMLX Income Statement

2023-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
Product revenue, net$ 102,693$ 345$ 272,337$ 345
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]us-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMemberus-gaap:ProductMember
Operating expenses:    
Cost of sales$ 5,218$ 172$ 16,081$ 172
Research and development30,03724,91483,27370,637
Selling, general and administrative48,71829,940136,11586,284
Total operating expenses83,97355,026235,469157,093
Income (loss) from operations18,720(54,681)36,868(156,748)
Other income, net:    
Interest income4,17960111,7841,134
Other (expense) income, net(488)199(831)138
Total other income, net3,69180010,9531,272
Income (loss) before income taxes22,411(53,881)47,821(155,476)
Provision (benefit) for income taxes1,518(125)3,281195
Net income (loss)$ 20,893$ (53,756)$ 44,540$ (155,671)
Net income (loss) per share attributable to common stockholders -basic$ 0.31$ (0.92)$ 0.66$ (2.77)
Net income (loss) per share attributable to common stockholders -diluted$ 0.3$ (0.92)$ 0.63$ (2.77)
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders-basic67,414,66958,533,22667,124,40756,163,194
Weighted-average shares used in computing net income (loss) per share attributable to common stockholders-diluted69,748,54758,533,22670,143,65956,163,194

AMLX Balance Sheet

2023-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 135,258$ 62,526
Short-term investments219,787284,419
Accounts receivable, net29,35315,306
Inventories32,3749,769
Prepaid expenses and other current assets17,33810,113
Total current assets434,110382,133
Property and equipment, net2,7612,611
Restricted cash equivalents719719
Operating lease right-of-use assets4,1895,524
Long-term inventories24,329 
Other assets476466
Total assets466,584391,453
Current liabilities:  
Accounts payable6,3716,257
Accrued expenses37,04538,312
Operating lease liabilities, current portion2,2012,040
Total current liabilities45,61746,609
Operating lease liabilities, net of current portion2,5674,237
Total liabilities48,18450,846
Commitments and contingencies (Note 13)
Stockholders' equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized no shares issued or outstanding
Common stock, $0.0001 par value; 300,000,000 shares authorized; 67,505,126 and 66,512,011 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively77
Additional paid-in capital728,224694,906
Accumulated deficit(309,680)(354,220)
Accumulated other comprehensive loss(151)(86)
Total stockholders' equity418,400340,607
Total liabilities, redeemable convertable preferred stock and stockholders' equity$ 466,584$ 391,453
AMLX
Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEamylyx.com
 EMPLOYEES338

Amylyx Pharmaceuticals, Inc. Frequently Asked Questions


What is the ticker symbol for Amylyx Pharmaceuticals, Inc.? What does AMLX stand for in stocks?

AMLX is the stock ticker symbol of Amylyx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Amylyx Pharmaceuticals, Inc. (AMLX)?

As of Thu Feb 22 2024, market cap of Amylyx Pharmaceuticals, Inc. is 1.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AMLX stock?

You can check AMLX's fair value in chart for subscribers.

What is the fair value of AMLX stock?

You can check AMLX's fair value in chart for subscribers. The fair value of Amylyx Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Amylyx Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AMLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Amylyx Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether AMLX is over valued or under valued. Whether Amylyx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Amylyx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AMLX.

What is Amylyx Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, AMLX's PE ratio (Price to Earnings) is 681.8 and Price to Sales (PS) ratio is 45.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AMLX PE ratio will change depending on the future growth rate expectations of investors.